Aptose Biosciences Inc reports results for the quarter ended September 30 - Earnings Summary
Aptose Biosciences Inc APTO.OQ reported a quarterly adjusted loss of 37 cents per share for the quarter ended September 30, higher than the same quarter last year, when the company reported EPS of $-1.76. The mean expectation of two analysts for the quarter was for a loss of $1.19 per share.
Reported revenue was zero; analysts expected zero.
Aptose Biosciences Inc's reported EPS for the quarter was a loss of 37 cents.
The company reported a quarterly loss of $6.95 million.
Aptose Biosciences Inc shares had fallen by 5.4% this quarter and lost 84.7% so far this year.
FORECAST CHANGES
The mean earnings estimate of analysts was unchanged in the last three months.
In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.
RECOMMENDATIONS
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."
The average consensus recommendation for the pharmaceuticals peer group is also "buy"
Wall Street's median 12-month price target for Aptose Biosciences Inc is $14.50
This summary was machine generated from LSEG data November 8 at 11:13 p.m. UTC. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
QUARTER ENDING | ESTIMATE | ACTUAL | BEAT, MET, MISSED |
Sep. 30 2024 | -1.19 | -0.37 | Beat |
Jun. 30 2024 | -1.18 | -0.43 | Beat |
Mar. 31 2024 | -0.74 | -0.73 | Beat |
Dec. 31 2023 | -1.59 | -1.44 | Beat |
免責聲明: XM Group提供線上交易平台的登入和執行服務，允許個人查看和/或使用網站所提供的內容，但不進行任何更改或擴展其服務和訪問權限，並受以下條款與條例約束：（i）條款與條例；（ii）風險提示；（iii）完全免責聲明。網站內部所提供的所有資訊，僅限於一般資訊用途。請注意，我們所有的線上交易平台內容並不構成，也不被視為進入金融市場交易的邀約或邀請 。金融市場交易會對您的投資帶來重大風險。
所有缐上交易平台所發佈的資料，僅適用於教育/資訊類用途，不包含也不應被視爲適用於金融、投資稅或交易相關諮詢和建議，或是交易價格紀錄，或是任何金融商品或非應邀途徑的金融相關優惠的交易邀約或邀請。
本網站的所有XM和第三方所提供的内容，包括意見、新聞、研究、分析、價格其他資訊和第三方網站鏈接，皆爲‘按原狀’，並作爲一般市場評論所提供，而非投資建議。請理解和接受，所有被歸類為投資研究範圍的相關内容，並非爲了促進投資研究獨立性，而根據法律要求所編寫，而是被視爲符合營銷傳播相關法律與法規所編寫的内容。請確保您已詳讀並完全理解我們的非獨立投資研究提示和風險提示資訊，相關詳情請點擊 這裡查看。
